All News
Filter News
Found 150 articles
-
Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024
2/8/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced a portfolio reprioritization.
-
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
1/5/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company remains on track to complete all Phase 2-enabling activities in 2023 for ALG-055009, its thyroid hormone receptor beta (THR-ß) drug candidate for nonalcoholic steatohepatitis (NASH).
-
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)Single and multiple ascending doses to be evaluated in CHB subjects throughout 2023
12/14/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with ALG-125755, a small interfering RNA (siRNA) targeting the production of hepatitis B surface antigen (HBsAg), was initiated in subjects with chronic hepatitis B (CHB) in Study ALG-125755-501 (NCT05561530).
-
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
12/8/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company presented the progress to date on the development of an oral pan-coronavirus therapeutic at the 2022 Respi DART meeting that was held December 6 – 8, 2022, in Los Cabos, Mexico.
-
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
11/2/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the third quarter, September 30, 2022.
-
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022
10/21/2022
Aligos Therapeutics, Inc. today announced seven upcoming poster presentations at The Liver Meeting® (November 4-8, 2022), hosted by the American Association for the Study of Liver Diseases (AASLD).
-
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
10/19/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”) today announced that it will report the company’s third quarter 2022 financial results on Wednesday, November 2, 2022 after the close of the U.S. financial markets.
-
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference
10/18/2022
Aligos Therapeutics, Inc. today announced that the Company will make an oral presentation at the Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference being held October 17-20, 2022 in Boston, MA.
-
Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
10/14/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with ALG-125755, an siRNA targeting the production of hepatitis B surface antigen (HBsAg), was initiated in healthy volunteers in Study ALG-125755-501 (NCT05561530).
-
This week had a flurry of biopharma patent cases, from Novartis vs Gilenya, Merck vs Viatris, and Aligos vs Janssen, either filed or court decisions being made.
-
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
8/4/2022
Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported recent business progress and financial results for the second quarter June 30, 2022.
-
Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022
7/27/2022
Aligos Therapeutics, Inc. announced that it will report the company’s second quarter 2022 financial results on Thursday, August 4, 2022 after the close of the U.S. financial markets.
-
Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184
7/25/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported that enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis B (CHB) subjects was initiated in the ongoing Phase 1b study ALG-000184-201 (NCT04536337).
-
Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184
6/22/2022
Aligos Therapeutics, Inc. today announced that the company is presenting two posters showcasing preliminary Phase 1 data from its capsid assembly modulator (CAM) program in CHB.
-
Aligos Therapeutics to Participate in Metropolitan AntiViral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential
6/6/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), today announced that the company will participate in the newly formed Metropolitan AntiViral Drug Accelerator (MAVDA) which was recently awarded a three-year, $65,141,731 grant from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Disease (NIAID)’s Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program.
-
Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference
5/23/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present in at the Jefferies Healthcare Conference.
-
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
5/4/2022
Aligos Therapeutics, Inc. reported recent business progress and financial results for the first quarter March 31, 2022.
-
Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs
5/3/2022
Aligos Therapeutics, Inc. today announced that the company will present three posters highlighting data from three of the company’s programs in chronic hepatitis B (CHB) at the European Association for the Study of the Liver’s International Liver Congress 2022.
-
Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
4/27/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s first quarter 2022 financial results on Wednesday, May 4, 2022 after the close of U.S. financial markets.
-
Stephane Bancel, the chief executive of Moderna, has likened the need for booster vaccine doses to the way Apple releases new smartphones every year.